Transcription Factor FoxO1 Mediates Glucagon-Like Peptide-1 Effects on Pancreatic β-Cell Mass
The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
The glucoincretin hormone glucagon-like peptide-1 (GLP-1) increases pancreatic β-cell proliferation and survival through sequential activation of the epidermal growth factor receptor (EGFR), phosphatidylinositol-3 kinase (PI 3-kinase), and Akt. We investigated the role of transcription factor FoxO1 in the proliferative and antiapoptotic actions of GLP-1 in β-cells. GLP-1 inhibited FoxO1 through phosphorylation-dependent nuclear exclusion in pancreatic β (INS832/13) cells. The effect of GLP-1 was suppressed by inhibitors of EGFR (AG1478) and PI 3-kinase (LY294002). In contrast, LY294002 but not AG1478 suppressed insulin-induced FoxO1 phosphorylation. Expression of constitutively nuclear FoxO1 in β-cells prevented the proliferative and antiapoptotic actions of GLP-1 in cultured β-cells and the increase in pancreatic β-cell mass in response to Exendin4 in transgenic mice. Gene expression and chromatin immunoprecipitation assays demonstrated that GLP-1 increases pancreatic and duodenal homeobox gene-1 and Foxa2 expression and inhibits FoxO1 binding to both promoters. We propose that FoxO1 mediates the pleiotropic effects of the glucoincretin hormone on cell proliferation and survival.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A 1-week daily injection of exendin-4 resulted in a twofold increase in β-cell mass (30).”
From Age-Dependent Decline in β-Cell Proliferation Restricts the Capacity of β-Cell Regeneration in Mice (2009) · cites this paper as [30]
Citations
Cites
(2004) · doi:10.1016/s0092-8674(04)00452-0 · Cited by 1,356 · cited 1×
“Because FoxO1 controls cell cycle progression (27), we examined whether its inhibition is required for GLP1-dependent -cell proliferation.”
BackgroundSelf-citationHohmeier, H. E., Mulder, H., Chen, G., Henkel-Rieger, R., Prentki, M., & Newgard, C. B. (2000) · Diabetes · doi:10.2337/diabetes.49.3.424 · Cited by 917 · cited 1×
“INS832/13 (22) cells (passage 36–70) were grown in RPMI 1640 medium supplemented with 10 mmol/l HEPES, 10% heat-inactivated FCS, 2 mmol/l L-glutamine, 1 mmol/l sodium pyruvate, 50 mol/l -mercaptoethanol, 100 IU/ml penicillin, and 100 g/ml streptomycin at 37°C in a humidified 5% CO2 atmosphere.”
Glucose Toxicity in β-Cells: Type 2 Diabetes, Good Radicals Gone Bad, and the Glutathione Connection
Robertson, R. P., Harmon, J., Tran, P. O., Tanaka, Y., & Takahashi, H. (2003) · Diabetes · doi:10.2337/diabetes.52.3.581 · Cited by 897
Gutniak, M., Ørkov, C., Holst, J. J., Ahrén, B., & Efendić, S. (1992) · New England Journal of Medicine · doi:10.1056/nejm199205143262003 · Cited by 868
Nakae, J., Kitamura, T., Silver, D. L., & Accili, D. (2001) · Journal of Clinical Investigation · doi:10.1172/jci12876 · Cited by 652 · cited 1×
“We next transduced cells with a constitutively nuclear FoxO1 mutant (20) or with control -gal adenovirus.”
MethodSelf-citationNakae, J., Kitamura, T., Silver, D. L., & Accili, D. (2001) · Journal of Clinical Investigation · doi:10.1172/jci200112876 · Cited by 652
Self-citationNakae, J., Biggs, W. H., Kitamura, T., Cavenee, W. K., Wright, C. V. E., Arden, K. C., & Accili, D. (2002) · Nature Genetics · doi:10.1038/ng890 · Cited by 616 · cited 4×
“The mutant transgene carries a single amino acid substitution replacing the main Akt phosphorylation site and is therefore constitutively nuclear (line 305) (19).”
BackgroundMethodSelf-citationHolz IV, G. G., Kiihtreiber, W. M., & Habener, J. F. (1993) · Nature · doi:10.1038/361362a0 · Cited by 594
Glucagon-like Peptide-1 Receptor Signaling Modulates β Cell Apoptosis
Li, Y., Hansotia, T., Yusta, B., Ris, F., Halban, P. A., & Drucker, D. J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m209423200 · Cited by 589
Kitamura, T., Nakae, J., Kitamura, Y., Kido, Y., Biggs, W., Wright, C. V. E., White, M. F., Arden, K. C., & Accili, D. (2002) · Journal of Clinical Investigation · doi:10.1172/jci16857 · Cited by 580 · cited 3×
“We have previously shown that FoxO1 inhibits Pdx1 expression, thereby providing a mechanism by which FoxO1 controls -cell proliferation and insulin secretion (18).”
BackgroundSelf-citation
Cited by
Biology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639
The role of incretins in glucose homeostasis and diabetes treatment
Kim, W., & Egan, J. M. (2008) · Pharmacological Reviews · doi:10.1124/pr.108.000604 · Cited by 824
“…localization of PDX-1 involves the phosphorylation of FoxO1 via transactivation of the EGFR and PI-3K/PKB pathway, resulting in deactivation and nuclear exclusion of FoxO1 and consequent disinhibition of Foxa2dependent pdx-1 gene promoter activity (Kitamura et al., 2002; Buteau et al., 2006).”
BackgroundMechanisms of action of glucagon-like peptide 1 in the pancreas
Doyle, M. E., & Egan, J. M. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2006.11.007 · Cited by 680
The role of gut hormones in glucose homeostasis
Drucker, D. J. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30076 · Cited by 614
The role of FoxO in the regulation of metabolism
Gross, D. N., van den Heuvel, A. P. J., & Birnbaum, M. J. (2008) · Oncogene · doi:10.1038/onc.2008.25 · Cited by 540
“Most notably, transgenic rescue of Pdx-1 expression in the beta cell alone is able to restore beta cell mass and function in the diabetic IRS-2 knockout mouse (Kushner et al., 2002).”
BackgroundInfluentialGraaf, C. D., Donnelly, D., Wootten, D., Lau, J., Sexton, P. M., Miller, L. J., Ahn, J.-M., Liao, J., Fletcher, M. M., Yang, D., et al. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011395 · Cited by 403
“Akt inhibits forkhead transcription factor (Foxo1) action through its nuclear exclusion, relieving its inhibition on expression of forkhead box protein A2, which controls PDX-1 expression (Kitamura et al., 2002; Buteau et al., 2006).”
BackgroundAge-Dependent Decline in β-Cell Proliferation Restricts the Capacity of β-Cell Regeneration in Mice
Tschen, S.-I., Dhawan, S., Gurlo, T., & Bhushan, A. (2009) · Diabetes · doi:10.2337/db08-1651 · Cited by 331
“Glucoincretin hormones GLP-1 and its long-acting peptide analogue exendin-4 have been suggested to induce -cell mass expansion by increasing -cell proliferation (30).”
BackgroundAnti-diabetic actions of glucagon-like peptide-1 on pancreatic beta-cells
Lee, Y.-S., & Jun, H.-S. (2014) · Metabolism · doi:10.1016/j.metabol.2013.09.010 · Cited by 315
“In addition, GLP-1 induces FoxO1 phosphorylation in INS 832/13 cells, which is blocked by inhibitors to PI3 kinase (LY294002) or EGFR (AG1478) [28], providing evidence that the effect of GLP-1-induced prolifer-”
BackgroundInfluentialRegulation of Glucose Homeostasis by GLP-1
Nadkarni, P., Chepurny, O. G., & Holz, G. G. (2014) · Progress in Molecular Biology and Translational Science · doi:10.1016/b978-0-12-800101-1.00002-8 · Cited by 287
Oeseburg, H., de Boer, R. A., Buikema, H., van der Harst, P., van Gilst, W. H., & Silljé, H. H. W. (2010) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.110.206425 · Cited by 267
Alonso, L. C., Yokoe, T., Zhang, P., Scott, D. K., Kim, S. K., O'Donnell, C. P., & Garcia-Ocaña, A. (2007) · Diabetes · doi:10.2337/db06-1513 · Cited by 252
FoxO1, the transcriptional chief of staff of energy metabolism
Kousteni, S. (2012) · Bone · doi:10.1016/j.bone.2011.06.034 · Cited by 238
“In insulin resistance, FoxO1 activity is unleashed and thus inhibits the increase in β-cell proliferation that is needed to compensate the rise in insulin demand [18–20].”
BackgroundErdogdu, Ö., Nathanson, D., Sjöholm, Å., Nyström, T., & Zhang, Q. (2010) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2010.04.022 · Cited by 229
Effects of Glucagon-Like Peptide-1 on Oxidative Stress and Nrf2 Signaling
Oh, Y., & Jun, H.-S. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms19010026 · Cited by 217
Verspohl, E. J. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.06.002 · Cited by 196
Minireview: Thioredoxin-Interacting Protein: Regulation and Function in the Pancreatic β-Cell
Shalev, A. (2014) · Molecular Endocrinology · doi:10.1210/me.2014-1095 · Cited by 185
Mayendraraj, A., Rosenkilde, M. M., & Gasbjerg, L. S. (2022) · Peptides · doi:10.1016/j.peptides.2022.170749 · Cited by 154
Cornu, M., Yang, J.-Y., Jaccard, E., Poussin, C., Widmann, C., & Thorens, B. (2009) · Diabetes · doi:10.2337/db09-0063 · Cited by 146
“GLP-1 has previously been demonstrated to protect -cells against apoptosis by increasing IRS-2 expression (14,16), PI 3-kinase activity (30), Akt phosphorylation (31) and Foxo1 phosphorylation, and nuclear exclusion (32).”
BackgroundPancreatic diabetes manifests when beta cell area declines by approximately 65% in humans
Meier, J. J., Breuer, T. G. K., Bonadonna, R. C., Tannapfel, A., Uhl, W. H., Schmidt, W. E., Schrader, H., & Menge, B. (2012) · Diabetologia · doi:10.1007/s00125-012-2466-8 · Cited by 160
“humans [11–15] and rodents [16].”
GLP-1 receptor signaling: effects on pancreatic β-cell proliferation and survival
Buteau, J. (2008) · Diabetes & Metabolism · doi:10.1016/s1262-3636(08)73398-6 · Cited by 158
Self-citationThe emerging role of FOXO transcription factors in pancreatic β cells
Glauser, D. A., & Schlegel, W. (2007) · Journal of Endocrinology · doi:10.1677/joe-06-0191 · Cited by 153
“…of Endocrinology (2007) 193, 195–207 cells, FOXO is phosphorylated following the activation of the PI3K–Akt pathway by insulin, IGF-I, glucose, glucagon-like peptide-1 (GLP-1), or glucose-dependent insulinotropic polypeptide (GIP) (Trumper et al. 2000, 2001, Wrede et al. 2002, Buteau et al. 2006).”
BackgroundPathomechanisms of Type 2 Diabetes Genes
Staiger, H., Machicao, F., Fritsche, A., & Häring, H.-U. (2009) · Endocrine Reviews · doi:10.1210/er.2009-0017 · Cited by 133
Human β-Cell Proliferation and Intracellular Signaling: Part 3
Stewart, A. F., Hussain, M. A., García-Ocaña, A., Vasavada, R. C., Bhushan, A., Bernal-Mizrachi, E., & Kulkarni, R. N. (2015) · Diabetes · doi:10.2337/db14-1843 · Cited by 142
“Whether GLP-1 enhances human b-cell proliferation is unclear, as one report reveals a modest increase in proliferation (85) and another indicates no increase in replication with GLP-1 analogs (36).”
BackgroundFOXO family in regulating cancer and metabolism
Ma, J., Matkar, S. S., He, X., & Hua, X. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.01.018 · Cited by 138
Pancreatic β-Cell Proliferation in Obesity
Linnemann, A. K., Baan, M., & Davis, D. B. (2014) · Advances in Nutrition · doi:10.3945/an.113.005488 · Cited by 132
ChREBP Mediates Glucose-Stimulated Pancreatic β-Cell Proliferation
Metukuri, M. R., Zhang, P., Basantani, M. K., Chin, C., Stamateris, R. E., Alonso, L. C., Takane, K. K., Gramignoli, R., Strom, S. C., O’Doherty, R. M., et al. (2012) · Diabetes · doi:10.2337/db11-0802 · Cited by 106
Targeting β-Cell Mass in Type 2 Diabetes: Promise and Limitations of New Drugs Based on Incretins
Salehi, M., Aulinger, B. A., & D'Alessio, D. A. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0031 · Cited by 109
Regulation of pancreatic β‐cell function by the forkhead protein FoxO1
Buteau, J., & Accili, D. (2007) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2007.00782.x · Cited by 103
Self-citationWideman, R. D., Yu, I. L. Y., Webber, T. D., Verchere, C. B., Johnson, J. D., Cheung, A. T., & Kieffer, T. J. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0600655103 · Cited by 108
Liu, Z., Tanabe, K., Bernal‐Mizrachi, E., & Permutt, M. A. (2008) · Diabetologia · doi:10.1007/s00125-007-0914-7 · Cited by 104
Cornu, M., Modi, H., Kawamori, D., Kulkarni, R. N., Joffraud, M., & Thorens, B. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.091116 · Cited by 92
Exendin-4 Stimulation of Cyclin A2 in β-Cell Proliferation
Song, W.-J., Schreiber, W. E., Zhong, E., Liu, F.-F., Kornfeld, B. D., Wondisford, F. E., & Hussain, M. A. (2008) · Diabetes · doi:10.2337/db07-1541 · Cited by 87
Akt and PTEN: β-cell mass and pancreas plasticity
Elghazi, L., & Bernal‐Mizrachi, E. (2009) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2009.03.002 · Cited by 98
Buteau, J., Shlien, A., Foisy, S., & Accili, D. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m606118200 · Cited by 98
Self-citationNew type 2 diabetes risk genes provide new insights in insulin secretion mechanisms
Schäfer, S., Machicao, F. E., Fritsche, A., Häring, H., & Kantartzis, K. (2011) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(11)70008-0 · Cited by 94
“proliferation and mass expansion in response to insulin resistance/ hyperinsulinemia and/or incretins [193,194].”
BackgroundFoxO1 as a tissue-specific therapeutic target for type 2 diabetes
Teaney, N. A., & Cyr, N. E. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1286838 · Cited by 89
Dipeptidyl peptidase IV (DPP IV) and related molecules in type 2 diabetes
Flatt, P. R. (2008) · Frontiers in bioscience · doi:10.2741/2956 · Cited by 89
Kibbe, C., Chen, J., Xu, G., Jing, G., & Shalev, A. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.473082 · Cited by 79
Portha, B., Tourrel-Cuzin, C., & Movassat, J. (2011) · Experimental Diabetes Research · doi:10.1155/2011/376509 · Cited by 85
“Nevertheless, GLP-1 triggers expression and nuclear localization of PDX-1 involves the phosphorylation of FoxO1 via transactivation of the EGFR and PI-3K/PKB pathway, resulting in deactivation and nuclear exclusion of FoxO1 and consequent disinhibition of Foxa2-dependent pdx-1 gene promoter activity [14, 15].”
BackgroundGirard, J. R. (2008) · Diabetes & Metabolism · doi:10.1016/j.diabet.2008.09.001 · Cited by 85
Dong, Z., Chai, W., Wang, W., Zhao, L., Fu, Z., Cao, W., & Liu, Z. (2013) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00473.2012 · Cited by 71
Green, C. J., Henriksen, T. I., Pedersen, B. K., & Solomon, T. P. J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0044284 · Cited by 80
Dzhura, I., Chepurny, O. G., Leech, C. A., Roe, M. W., Dzhura, E., Xu, X., Lu, Y., Schwede, F., Genieser, H.-G., Smrcka, A. V., et al. (2011) · Islets · doi:10.4161/isl.3.3.15507 · Cited by 78
Zhong, J., Gong, Q., Goud, A., Srinivasamaharaj, S., & Rajagopalan, S. (2015) · Journal of Diabetes Research · doi:10.1155/2015/606031 · Cited by 72
“Foxa2 then increases PDX-1, a transcription factor for insulin [83].”
BackgroundFormation and regeneration of the endocrine pancreas
Dhawan, S., Georgia, S. K., & Bhushan, A. (2007) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2007.09.015 · Cited by 79
Zhang, Y., Zhen, W., Maechler, P., & Liu, D. (2013) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2012.03.008 · Cited by 72
“The transcriptional activity of FoxO1 is inhibited upon phosphorylation by Akt and subsequent nuclear exclusion [44].”
The benefits of physical exercise for the health of the pancreatic β‐cell: a review of the evidence
Curran, M., Drayson, M. T., Andrews, R. C., Zoppi, C., Barlow, J. P., Solomon, T. P. J., & Narendran, P. (2020) · Experimental Physiology · doi:10.1113/ep088220 · Cited by 67
Kapodistria, K., Tsilibary, E., Kotsopoulou, E., Moustardas, P., & Kitsiou, P. (2018) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.13259 · Cited by 67
Cochran, B. J., Bisoendial, R. J., Hou, L., Glaros, E. N., Rossy, J., Thomas, S. R., Barter, P. J., & Rye, K.-A. (2014) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.114.304131 · Cited by 70
Paracrine signaling in islet function and survival
Hartig, S. M., & Cox, A. R. (2020) · Journal of Molecular Medicine · doi:10.1007/s00109-020-01887-x · Cited by 69
GLP-1 and type 2 diabetes: physiology and new clinical advances
Combettes, M. (2006) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2006.08.003 · Cited by 69
Fernández‐Millán, E., Martín, M. Á., Goya, L., Lizárraga-Mollinedo, E., Escrivá, F., Ramos, S., & Álvarez, C. (2016) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2016.03.002 · Cited by 68
EGF receptor in pancreatic β-cell mass regulation
Miettinen, P. J., Ormio, P., Hakonen, E. T., Banerjee, M., & Otonkoski, T. (2008) · Biochemical Society Transactions · doi:10.1042/bst0360280 · Cited by 66
Genetic and biochemical pathways of β‐cell failure in type 2 diabetes
Talchai, C., Lin, H. V., Kitamura, T., & Accili, D. (2009) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01115.x · Cited by 63
Self-citationGlucagon-Like Peptide-1 and Energy Homeostasis3
Burcelin, R., Cani, P. D., & Knauf, C. (2007) · Journal of Nutrition · doi:10.1093/jn/137.11.2534s · Cited by 66
Bouzakri, K., Ribaux, P., Tomas, A., Parnaud, G., Rickenbach, K., & Halban, P. A. (2008) · Diabetes · doi:10.2337/db07-1469 · Cited by 59
Gastrointestinal hormones and the regulation of β‐cell mass
Lavine, J. A., & Attie, A. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2010.05802.x · Cited by 63
Li, Y., Deng, S., Peng, J., Wang, X., Essandoh, K., Mu, X., Peng, T., Meng, Z.-X., & Fan, G. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.007755 · Cited by 60
“For example, Foxo1 inhibition is required for the proliferative effects of GLP-1 on -cells (34).”
BackgroundYang, H., Nkeze, J., & Zhao, Y. (2012) · Cell & Bioscience · doi:10.1186/2045-3701-2-32 · Cited by 60
Protective Action of Liraglutide in Beta Cells Under Lipotoxic Stress Via PI3K/Akt/FoxO1 Pathway
Shao, S., Nie, M., Chen, C., Chen, X., Zhang, M., Yuan, G., Yu, X., & Yang, Y. (2014) · Journal of Cellular Biochemistry · doi:10.1002/jcb.24763 · Cited by 55
Bastien-Dionne, P.-O., Valenti, L., Kon, N., Gu, W., & Buteau, J. (2011) · Diabetes · doi:10.2337/db11-0101 · Cited by 53
“We have previously shown that inhibition of the forkhead transcription factor FoxO1 mediates the pleiotropic action of the glucoincretin hormone GLP-1 (10).”
BackgroundResultSelf-citationGlucagon-Like Peptide 1 Analogs and their Effects on Pancreatic Islets
Tudurí, E., López, M., Diéguez, C., Nadal, Á., & Nogueiras, R. (2016) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2016.03.004 · Cited by 56
“In vitro studies in INS(832/13) cells have shown that GLP-1 induces the trans-phosphorylation of EGFR [57], subsequent activation of the PI3K/Akt pathway [58], and phosphorylation and nuclear exclusion of FOXO1 [59].”
BackgroundBiswas, S. C., Buteau, J., & Greene, L. A. (2008) · Neurochemical Research · doi:10.1007/s11064-008-9646-4 · Cited by 55
Self-citationApolipoprotein A-I interactions with insulin secretion and production
Rye, K., Barter, P. J., & Cochran, B. J. (2015) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000253 · Cited by 55
Guðmundsdóttir, V., Pedersen, H., Allebrandt, K. V., Brorsson, C., van Leeuwen, N., Banasik, K., Mahajan, A., Groves, C. J., van de Bunt, M., Dawed, A. Y., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0189886 · Cited by 52
“It contained genes already known to be involved in GLP-1 stimulated insulin secretion (WFS1 [5], RYR2 [15], RAP1A [16]), glucose stimulated insulin secretion (VAV2 [17]), mediating the effects of GLP-1 on beta-cell mass (FOXO1 [18]) and genes implicated in type 2 diabetes through GWAS of Han Chinese [19] and Mexican […”
BackgroundA role for the gut-to-brain GLP-1-dependent axis in the control of metabolism
Burcelin, R., Sérino, M., & Cabou, C. (2009) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2009.09.003 · Cited by 52
Bednářová, A., Kodrík, D., & Krishnan, N. (2012) · Comparative Biochemistry and Physiology Part A Molecular & Integrative Physiology · doi:10.1016/j.cbpa.2012.10.012 · Cited by 52
Recent Advances in Antidiabetic Drug Therapies Targeting the Enteroinsular Axis
Flatt, P., Bailey, C., & Green, B. (2009) · Current Drug Metabolism · doi:10.2174/138920009787522124 · Cited by 46
GLP-1 agonists in type 1 diabetes
Pettus, J., Hirsch, I. B., & Edelman, S. V. (2013) · Clinical Immunology · doi:10.1016/j.clim.2013.04.006 · Cited by 48
“GLP-1 has also indicated an effect on transcriptional factors such as FoxO1, PDX-1, Foxa2 and others that have been implicated in enhanced beta cell health [10,11].”
BackgroundPleiotropic Actions of the Incretin Hormones
McIntosh, C. H. S., Widenmaier, S. B., & Kim, S. (2010) · Vitamins and hormones · doi:10.1016/b978-0-12-381517-0.00002-3 · Cited by 46
Takamoto, I., Terauchi, Y., Kubota, N., Ohsugi, M., Ueki, K., & Kadowaki, T. (2008) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00951.x · Cited by 46
Wewer Albrechtsen, N. J., Albrechtsen, R., Bremholm, L., Svendsen, B., Kuhre, R. E., Poulsen, S. S., Christiansen, C. B., Jensen, E. P., Janus, C., Hilsted, L., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.11.051 · Cited by 40
“We therefore tested whether GLP-1-induced cell proliferation was mediated by c-Src/EGFR related pathways (c-Src, epidermal growth factor receptor [EGFR], phosphatidylinositol 3-kinase [PI3K], and Foxo1), as reported for pancreatic b cells (Buteau et al., 2006).”
BackgroundThe Identification of Novel Proteins That Interact With the GLP-1 Receptor and Restrain its Activity
Huang, X., Dai, F. F., Gaisano, G., Giglou, K., Han, J., Zhang, M., Kittanakom, S., Wong, V., Li, W., Showalter, A. D., et al. (2013) · Molecular Endocrinology · doi:10.1210/me.2013-1047 · Cited by 45
Urkon, M., Ferencz, E., Szász, J. A., Szabó, M. I. M., Orbán-Kis, K., Szatmári, S., & Nagy, E. E. (2025) · Pharmaceuticals · doi:10.3390/ph18050614 · Cited by 45
“The PI3K/Akt/mTOR pathway activation [67] is thought to mediate the GLP-1’s anti-apoptotic [70,71] and neurotrophic potential [72–74].”
Talbot, J., Joly, E. C., Prentki, M., & Buteau, J. (2012) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2012.08.010 · Cited by 43
Self-citationTramutola, A., Arena, A., Cini, C., Butterfield, D. A., & Barone, E. (2017) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2017.1246183 · Cited by 38
Incretin-based therapies in prediabetes: Current evidence and future perspectives
Papaetis, G. S. (2014) · World Journal of Diabetes · doi:10.4239/wjd.v5.i6.817 · Cited by 37
A Critical Role for the Neural Zinc Factor ST18 in Pancreatic β-Cell Apoptosis
Henry, C., Close, A.-F., & Buteau, J. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.554915 · Cited by 41
Self-citationKolovou, G. D., Kolovou, V., & Mavrogeni, S. I. (2014) · BioMed Research International · doi:10.1155/2014/808307 · Cited by 40
A Simple Matter of Life and Death—The Trials of Postnatal Beta-Cell Mass Regulation
Tarabra, E., Pelengaris, S., & Khan, M. (2012) · International Journal of Endocrinology · doi:10.1155/2012/516718 · Cited by 40
“It was reported that exogenous GLP-1 treatment enhances beta-cell replication in normoglycaemic rats [100] and mice [101–105].”
BackgroundWeighing up β-cell mass in mice and humans: Self-renewal, progenitors or stem cells?
Hanley, N. A., Hanley, K. P., Miettinen, P. J., & Otonkoski, T. (2008) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2008.03.001 · Cited by 40
Glucagon-like peptide–1 and candesartan additively improve glucolipotoxicity in pancreatic β-cells
Wang, H.-W., Mizuta, M., Saitoh, Y., Noma, K., Ueno, H., & Nakazato, M. (2011) · Metabolism · doi:10.1016/j.metabol.2010.11.004 · Cited by 38
Arredouani, A. (2025) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2025.108824 · Cited by 36
Effects of phycocyanin on INS-1 pancreatic β-cell mediated by PI3K/Akt/FoxO1 signaling pathway
Gao, Y., Liao, G., Xiang, C., Yang, X., Cheng, X., & Ou, Y. (2015) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2015.11.054 · Cited by 36
Nov/Ccn3, a Novel Transcriptional Target of FoxO1, Impairs Pancreatic β-Cell Function
Paradis, R., Lazar, N., Antinozzi, P. A., Perbal, B., & Buteau, J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0064957 · Cited by 35
Self-citationSkp2 Is Required for Incretin Hormone-Mediated β-Cell Proliferation
Tschen, S.-I., Georgia, S., Dhawan, S., & Bhushan, A. (2011) · Molecular Endocrinology · doi:10.1210/me.2011-1119 · Cited by 33
“Several previous studies have shown that GLP-1 functions via the Irs2-PI3-kinase pathway to regulate the growth and survival of pancreatic -cells (4, 5, 16).”
BackgroundMethodInfluentialUpdate on the Protective Molecular Pathways Improving Pancreatic Beta-Cell Dysfunction
Puddu, A., Sanguineti, R., Mach, F., Dallegri, F., Viviani, G. L., & Montecucco, F. (2013) · Mediators of Inflammation · doi:10.1155/2013/750540 · Cited by 35
Pancreatic Glucokinase Is Activated by Insulin-Like Growth Factor-I
Yoshida, K., Murao, K., Imachi, H., Cao, W. M., Yu, X., Li, J., Ahmed, R. A. M., Kitanaka, N., Wong, N. C. W., Unterman, T. G., et al. (2007) · Endocrinology · doi:10.1210/en.2006-1149 · Cited by 34
“pancreatic duodenal homeobox-1, Foxa2, and peroxisomal proliferator-activated receptor- 2 (42, 43).”
Menin and PRMT5 suppress GLP1 receptor transcript and PKA-mediated phosphorylation of FOXO1 and CREB
Muhammad, A. B., Xing, B., Liu, C., Naji, A., Ma, X., Simmons, R. A., & Hua, X. (2017) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00241.2016 · Cited by 34
Lin, P., Chen, L., Li, D., Liu, J., Yang, N., Sun, Y., Xu, Y., Fu, Y., & Hou, X. (2009) · The Tohoku Journal of Experimental Medicine · doi:10.1620/tjem.217.59 · Cited by 33
“Similarly, the glucoincretin hormone glucagon-like peptide-1 (GLP-1), as a newly developed drug for diabetes, has been proven to inhibit foxO1 through nuclear exclusion, resulting in the improvement of β -cell longevity and key mRNA expression (Buteau et al. 2006).”
BackgroundGupta, D., Leahy, A. A., Monga, N., Peshavaria, M., Jetton, T. L., & Leahy, J. L. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.486852 · Cited by 33
Glucagon‐like peptide‐1: modulator of β ‐cell dysfunction and death
Rondas, D., D'Hertog, W., Overbergh, L., & Mathieu, C. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12165 · Cited by 32
β-Cell specific transcription factors in the context of diabetes mellitus and β-cell regeneration
Balakrishnan, S., Dhavamani, S., & Prahalathan, C. (2020) · Mechanisms of Development · doi:10.1016/j.mod.2020.103634 · Cited by 32
Alhajahjeh, A. A., Al‐Faouri, R., Bahmad, H. F., Bader, T., Dobbs, R. W., Abdulelah, A., Abou-Kheir, W. G., Davicioni, E., Lee, D. I., & Shahait, M. (2024) · Cancers · doi:10.3390/cancers16081538 · Cited by 32
“Additionally, GLP-1 has a collective impact on PDX1 by enhancing its activity and expression, contributing to the stimulation of cellular proliferation [13,14].”
BackgroundIncrease of INS-1 cell apoptosis under glucose fluctuation and the involvement of FOXO–SIRT pathway
Kim, M.-K., Chung, H. S., Yoon, C. S., Lee, E., Kim, T., Kim, T., Kwon, M., Lee, S., Rhee, B.-D., & Park, J. (2012) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2012.04.013 · Cited by 32
“[29] Buteau J, Spatz ML, Accili D.”
BackgroundGong, Q., Rajagopalan, S., & Zhong, J. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.06.076 · Cited by 32
Xu, Q. R., Chen, S., Deng, L., Feng, L., Huang, L., & Yu, R.-H. (2013) · Brazilian Journal of Medical and Biological Research · doi:10.1590/1414-431x20133163 · Cited by 30
“As oxidative stress progresses, pancreatic b cells slowly die, and proliferation of new pancreatic b cells is inhibited by FOXO1 activation (17), causing absolute insulin deficiency.”
BackgroundLeptin and adiponectin regulate compensatory beta cell growth in accordance to overweight
Huypens, P. (2006) · Medical Hypotheses · doi:10.1016/j.mehy.2006.09.046 · Cited by 30
“For instance, the incretins GIP and GLP-1 increase IRS-2 expression levels in beta cells by stimulating the cAMP-PKA-CREB pathway [14–17].”
BackgroundArumugam, R., Fleenor, D. E., Lu, D., & Freemark, M. (2011) · Endocrinology · doi:10.1210/en.2010-1258 · Cited by 29
Lamont, B. J., & Andrikopoulos, S. (2014) · Journal of Endocrinology · doi:10.1530/joe-13-0577 · Cited by 28
Metadata
- Authors
- Buteau, J., Spatz, M. L., & Accili, D.
- Affiliations
- Columbia University Irving Medical Center (US)
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2006-05-01
- Volume
- 55
- Issue
- 5
- Pages
- 1190-1196
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2122464768
- Cited by
- 178
- References
- 38
- Citations by year
- 2026: 3 · 2025: 6 · 2024: 2 · 2023: 6 · 2022: 5 · 2021: 2 · 2020: 5 · 2019: 3 · 2018: 6 · 2017: 7 · 2016: 12 · 2015: 11 · 2014: 13 · 2013: 10 · 2012: 15
- FWCI
- 16.61
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (DK-64819, R01DK064819)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › FOXO transcription factor regulation
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- FOXO1, glucagon-like peptide-1, beta-cell mass, beta-cell proliferation, beta-cell apoptosis, nuclear exclusion, EGFR signaling, PI3K/Akt signaling, exendin-4, PDX1, FOXA2, transcriptional regulation, insulin
- MeSH terms
- Forkhead Box Protein O1, Animals, Cell Division, Cell Line, Cell Survival, Glucagon-Like Peptides, Glucagon, Glucose, Insulin, Islets of Langerhans, Mice, Transgenic, Peptide Fragments, Green Fluorescent Proteins, Mice, Forkhead Transcription Factors, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.